Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Neuroleptic or [[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class IC)]]

Use the filters below to narrow your results.

generic:
Asenapine (1) · Chlorpromazine (1) · Droperidol (1) · Flecainide (1) · Fluphenazine (1) · Iloperidone (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Paliperidone (1) · Perphenazine (1) · Pimozide (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)
brand:
Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Tambocor (US brand discontinued) (1) · Thorazine (1) · Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Phenothiazine D2 antagonist (4) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-0000113A-QINU`"' Concomitant β-blocker or CCB is required when used for AF to prevent 1:1 atrial flutter conduction (flecainide can slow atrial rate to a level where AV conduction allows dangerous ventricular rates). CYP2D6 substrate'"`UNIQ--ref-0000113B-QINU`"'. (1)
uses:
None (15) · '"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"' (1)
starting dose:
None (15) · 50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion (1)
preparations:
None (15) · 50, 100, 150 mg tablets (1)
fda max:
None (15) · 400 mg/d (1)
routes:
None (15) · Oral (1)
onset:
None (15) · AF conversion within hours of single PO dose (1)
duration:
None (15) · 12 hours (1)
halflife:
None (15) · ~14 hours (adults); longer in elderly and renal impairment'"`UNIQ--ref-0000113F-QINU`"' (1)
bioavailability:
None (15) · ~90% (oral)'"`UNIQ--ref-00001140-QINU`"' (1)
pregnancy:
None (15) · Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (15) · [[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated in structural heart disease''' — CAST trial (1989) showed increased mortality from class IC agents in patients with prior MI; modern use is limited to structurally normal hearts'"`UNIQ--ref-00001141-QINU`"' (1)

Showing below up to 16 results in range #1 to #16.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"